Gisadenafil besylate

Cat. No. 4165 1 次引用提交评论说明书 / 分析证书（CoA） / 化学品安全技术说明书（SDS）

Pricing	Availability		Qty

说明： Potent PDE5 inhibitor; orally bioavailable

别名： UK 369003

化学名： 5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one benzenesulfonate

纯度： ≥99% (HPLC)

引用文献 (1)

生物活性技术数据溶解性计算器说明书参考文献

生物活性 for Gisadenafil besylate

Gisadenafil besylate is a potent PDE5 inhibitor (IC₅₀ = 1.23 nM). Shows >100-fold selectivity for PDE5 over PDE6. Orally bioavailable.

许可信息

Sold for research purposes under agreement from Pfizer Inc.

化合物库 for Gisadenafil besylate

Gisadenafil besylate is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。

技术数据 for Gisadenafil besylate

分子量	677.79
公式	C₂₃H₃₃N₇O₅S.C₆H₆O₃S
储存	Desiccate at RT
纯度	≥99% (HPLC)
CAS Number	334827-98-4
PubChem ID	23449797
InChI Key	STFRDYSZKVPPQF-UHFFFAOYSA-N
Smiles	O=S(C1=CN=C(OCC)C(C3=NC(C2=NN(CCOC)C(CC)=C2N3)=O)=C1)(N4CCN(CC)CC4)=O.O=S(C5=CC=CC=C5)(O)=O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for Gisadenafil besylate

	溶剂	最高浓度 mg/mL	最高浓度 mM
溶解性
	water	6.78	10
	DMSO	67.78	100

制备储备液 for Gisadenafil besylate

以下数据基于产品分子量 677.79。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

浓度/溶剂体积/质量	1 mg	5 mg	10 mg
1 mM	1.48 mL	7.38 mL	14.75 mL
5 mM	0.3 mL	1.48 mL	2.95 mL
10 mM	0.15 mL	0.74 mL	1.48 mL
50 mM	0.03 mL	0.15 mL	0.3 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

产品说明书 for Gisadenafil besylate

分析证书/产品说明书

化学品安全技术说明书

参考文献 for Gisadenafil besylate

参考文献是支持产品生物活性的出版物。

Hashim and Abrams (2010) Emerging drugs for the treatment of benign prostatic obstruction. Exp.Opin.Invest.Drugs 15 159 PMID: 20446824

Rawson et al (2012) The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. Bioorg.Med.Chem. 20 498 PMID: 22100260

If you know of a relevant reference for Gisadenafil besylate, please let us know.

按标靶查看相关产品

Phosphodiesterases

按产品操作查看相关产品

查看全部 Phosphodiesterase Inhibitors

关键词: Gisadenafil besylate, Gisadenafil besylate supplier, pfizer, phosphodiesterases, inhibitors, inhibits, PDE5, UK369003, UK, 369003, Phosphodiesterases, 4165, Tocris Bioscience

1 篇 Gisadenafil besylate 的引用文献

引用文献是使用了 Tocris 产品的出版物。 Gisadenafil besylate 的部分引用包括：

Silva et al (2012) Transient hypercapnia reveals an underlying cerebrovascular pathology in a murine model for HIV-1 associated neuroinflammation: role of NO-cGMP signaling and normalization by inhibition of cyclic nucleotide phosphodiesterase-5. J Neuroinflammation 9 253 PMID: 23167821

您是否知道使用了 Tocris Gisadenafil besylate 的优秀论文？请告知我们.